A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male Subjects
Clinical trial NCT06159101 · UNKNOWN
Trial details
- NCT number
- NCT06159101
- Sponsor
- Shanghai Henlius Biotech
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-28
- Primary completion
- 2024-05-28
- Enrollment
- 304
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.